Human Hepatocyte-Derived Induced Pluripotent Stem Cells: MYC Expression, Similarities to Human Germ Cell Tumors, and Safety Issues.

Détails

Ressource 1Télécharger: SCI2016-4370142.pdf (30450.80 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_16BC09A30781
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Human Hepatocyte-Derived Induced Pluripotent Stem Cells: MYC Expression, Similarities to Human Germ Cell Tumors, and Safety Issues.
Périodique
Stem cells international
Auteur⸱e⸱s
Unzu C., Friedli M., Bosman A., Jaconi M.E., Wildhaber B.E., Rougemont A.L.
ISSN
1687-966X (Print)
Statut éditorial
Publié
Date de publication
2016
Peer-reviewed
Oui
Volume
2016
Pages
4370142
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Induced pluripotent stem cells (iPSC) are a most promising approach to the development of a hepatocyte transplantable mass sufficient to induce long-term correction of inherited liver metabolic diseases, thus avoiding liver transplantation. Their intrinsic self-renewal ability and potential to differentiate into any of the three germ layers identify iPSC as the most promising cell-based therapeutics, but also as drivers of tumor development. Teratoma development currently represents the gold standard to assess iPSC pluripotency. We analyzed the tumorigenic potential of iPSC generated from human hepatocytes (HEP-iPSC) and compared their immunohistochemical profiles to that of tumors developed from fibroblast and hematopoietic stem cell-derived iPSC. HEP-iPSC generated tumors significantly presented more malignant morphological features than reprogrammed fibroblasts or CD34+ iPSC. Moreover, the protooncogene myc showed the strongest expression in HEP-iPSC, compared to only faint expression in the other cell subsets. Random integration of transgenes and the use of potent protooncogenes such as myc might be a risk factor for malignant tumor development if hepatocytes are used for reprogramming. Nonviral vector delivery systems or reprogramming of cells obtained from less invasive harvesting methods would represent interesting options for future developments in stem cell-based approaches for liver metabolic diseases.

Pubmed
Open Access
Oui
Création de la notice
16/12/2015 13:27
Dernière modification de la notice
20/08/2019 13:46
Données d'usage